- Home
- RGLS vs FBLG Comparison
RGLS vs FBLG Comparison
Compare RGLS & FBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGLS
- FBLG
- Stock Information
- Founded
- RGLS 2007
- FBLG 2021
- Country
- RGLS United States
- FBLG United States
- Employees
- RGLS N/A
- FBLG N/A
- Industry
- RGLS Biotechnology: Pharmaceutical Preparations
- FBLG
- Sector
- RGLS Health Care
- FBLG
- Exchange
- RGLS Nasdaq
- FBLG NYSE
- Market Cap
- RGLS 74.0M
- FBLG 67.7M
- IPO Year
- RGLS 2012
- FBLG 2024
- Fundamental
- Price
- RGLS $1.31
- FBLG $1.13
- Analyst Decision
- RGLS Strong Buy
- FBLG Strong Buy
- Analyst Count
- RGLS 6
- FBLG 4
- Target Price
- RGLS $10.33
- FBLG $13.00
- AVG Volume (30 Days)
- RGLS 820.1K
- FBLG 524.8K
- Earning Date
- RGLS 03-20-2025
- FBLG 03-04-2025
- Dividend Yield
- RGLS N/A
- FBLG N/A
- EPS Growth
- RGLS N/A
- FBLG N/A
- EPS
- RGLS N/A
- FBLG N/A
- Revenue
- RGLS N/A
- FBLG N/A
- Revenue This Year
- RGLS N/A
- FBLG N/A
- Revenue Next Year
- RGLS N/A
- FBLG N/A
- P/E Ratio
- RGLS N/A
- FBLG N/A
- Revenue Growth
- RGLS N/A
- FBLG N/A
- 52 Week Low
- RGLS $0.83
- FBLG $1.06
- 52 Week High
- RGLS $3.79
- FBLG $14.70
- Technical
- Relative Strength Index (RSI)
- RGLS 53.78
- FBLG 32.20
- Support Level
- RGLS $1.22
- FBLG $1.12
- Resistance Level
- RGLS $1.60
- FBLG $1.32
- Average True Range (ATR)
- RGLS 0.13
- FBLG 0.20
- MACD
- RGLS 0.03
- FBLG -0.03
- Stochastic Oscillator
- RGLS 50.85
- FBLG 6.91
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
About FBLG FIBROBIOLOGICS INC
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.